Literature DB >> 27581978

Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.

Zeli Zhang1, Qinyong Gu1, Ananda Ayyappan Jaguva Vasudevan1, Manimehalai Jeyaraj1, Stanislaw Schmidt2, Jörg Zielonka1, Mario Perković1,2, Jens-Ove Heckel3, Klaus Cichutek2, Dieter Häussinger1, Sander H J Smits4, Carsten Münk5.   

Abstract

Lentiviruses have evolved the Vif protein to counteract APOBEC3 (A3) restriction factors by targeting them for proteasomal degradation. Previous studies have identified important residues in the interface of human immunodeficiency virus type 1 (HIV-1) Vif and human APOBEC3C (hA3C) or human APOBEC3F (hA3F). However, the interaction between primate A3C proteins and HIV-1 Vif or natural HIV-1 Vif variants is still poorly understood. Here, we report that HIV-1 Vif is inactive against A3Cs of rhesus macaques (rhA3C), sooty mangabey monkeys (smmA3C), and African green monkeys (agmA3C), while HIV-2, African green monkey simian immunodeficiency virus (SIVagm), and SIVmac Vif proteins efficiently mediate the depletion of all tested A3Cs. We identified that residues N/H130 and Q133 in rhA3C and smmA3C are determinants for this HIV-1 Vif-triggered counteraction. We also found that the HIV-1 Vif interaction sites in helix 4 of hA3C and hA3F differ. Vif alleles from diverse HIV-1 subtypes were tested for degradation activities related to hA3C. The subtype F-1 Vif was identified to be inactive for degradation of hA3C and hA3F. The residues that determined F-1 Vif inactivity in the degradation of A3C/A3F were located in the C-terminal region (K167 and D182). Structural analysis of F-1 Vif revealed that impairing the internal salt bridge of E171-K167 restored reduction capacities to A3C/A3F. Furthermore, we found that D101 could also form an internal interaction with K167. Replacing D101 with glycine and R167 with lysine in NL4-3 Vif impaired its counteractivity to A3F and A3C. This finding indicates that internal interactions outside the A3 binding region in HIV-1 Vif influence the capacity to induce degradation of A3C/A3F. IMPORTANCE: The APOBEC3 restriction factors can serve as potential barriers to lentiviral cross-species transmissions. Vif proteins from lentiviruses counteract APOBEC3 by proteasomal degradation. In this study, we found that monkey-derived A3C, rhA3C and smmA3C, were resistant to HIV-1 Vif. This was determined by A3C residues N/H130 and Q133. However, HIV-2, SIVagm, and SIVmac Vif proteins were found to be able to mediate the depletion of all tested primate A3C proteins. In addition, we identified a natural HIV-1 Vif (F-1 Vif) that was inactive in the degradation of hA3C/hA3F. Here, we provide for the first time a model that explains how an internal salt bridge of E171-K167-D101 influences Vif-mediated degradation of hA3C/hA3F. This finding provides a novel way to develop HIV-1 inhibitors by targeting the internal interactions of the Vif protein.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27581978      PMCID: PMC5105656          DOI: 10.1128/JVI.01497-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  88 in total

1.  Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.

Authors:  Ying Dang; Roderick W Davis; Ian A York; Yong-Hui Zheng
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

2.  Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet.

Authors:  Mario Perkovic; Stanislaw Schmidt; Daniela Marino; Rebecca A Russell; Benjamin Stauch; Henning Hofmann; Ferdinand Kopietz; Björn-Philipp Kloke; Jörg Zielonka; Heike Ströver; Johannes Hermle; Dirk Lindemann; Vinay K Pathak; Gisbert Schneider; Martin Löchelt; Klaus Cichutek; Carsten Münk
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

Review 3.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

4.  The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.

Authors:  Shingo Kitamura; Hirotaka Ode; Masaaki Nakashima; Mayumi Imahashi; Yuriko Naganawa; Teppei Kurosawa; Yoshiyuki Yokomaku; Takashi Yamane; Nobuhisa Watanabe; Atsuo Suzuki; Wataru Sugiura; Yasumasa Iwatani
Journal:  Nat Struct Mol Biol       Date:  2012-09-23       Impact factor: 15.369

5.  Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids.

Authors:  Jörg Zielonka; Daniela Marino; Henning Hofmann; Naoya Yuhki; Martin Löchelt; Carsten Münk
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

6.  APOBEC3F determinants of HIV-1 Vif sensitivity.

Authors:  Allison M Land; Nadine M Shaban; Leah Evans; Judd F Hultquist; John S Albin; Reuben S Harris
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

7.  Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases.

Authors:  Renaud Mahieux; Rodolphe Suspène; Frédéric Delebecque; Michel Henry; Olivier Schwartz; Simon Wain-Hobson; Jean-Pierre Vartanian
Journal:  J Gen Virol       Date:  2005-09       Impact factor: 3.891

8.  A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.

Authors:  Anjie Zhen; Tao Wang; Ke Zhao; Yong Xiong; Xiao-Fang Yu
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

9.  Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Authors:  Véronique Zennou; Paul D Bieniasz
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

10.  HIV-1 Vif adaptation to human APOBEC3H haplotypes.

Authors:  Marcel Ooms; Bonnie Brayton; Michael Letko; Susan M Maio; Christopher D Pilcher; Frederick M Hecht; Jason D Barbour; Viviana Simon
Journal:  Cell Host Microbe       Date:  2013-10-16       Impact factor: 21.023

View more
  7 in total

1.  Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5.

Authors:  Qinyong Gu; Zeli Zhang; Christoph G W Gertzen; Dieter Häussinger; Holger Gohlke; Carsten Münk
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

2.  Multifaceted HIV-1 Vif interactions with human E3 ubiquitin ligase and APOBEC3s.

Authors:  Yingxia Hu; Kirsten M Knecht; Qi Shen; Yong Xiong
Journal:  FEBS J       Date:  2020-09-21       Impact factor: 5.542

3.  Divergence in Dimerization and Activity of Primate APOBEC3C.

Authors:  Amit Gaba; Mark A Hix; Sana Suhail; Ben Flath; Brock Boysan; Danielle R Williams; Tomas Pelletier; Michael Emerman; Faruck Morcos; G Andrés Cisneros; Linda Chelico
Journal:  J Mol Biol       Date:  2021-10-16       Impact factor: 6.151

4.  Stably expressed APOBEC3H forms a barrier for cross-species transmission of simian immunodeficiency virus of chimpanzee to humans.

Authors:  Zeli Zhang; Qinyong Gu; Marc de Manuel Montero; Ignacio G Bravo; Tomas Marques-Bonet; Dieter Häussinger; Carsten Münk
Journal:  PLoS Pathog       Date:  2017-12-21       Impact factor: 6.823

5.  Natural APOBEC3C variants can elicit differential HIV-1 restriction activity.

Authors:  Brett D Anderson; Terumasa Ikeda; Seyed Arad Moghadasi; Amber St Martin; William L Brown; Reuben S Harris
Journal:  Retrovirology       Date:  2018-12-17       Impact factor: 4.602

Review 6.  Feline APOBEC3s, Barriers to Cross-Species Transmission of FIV?

Authors:  Zeli Zhang; Qinyong Gu; Daniela Marino; Kyeong-Lim Lee; Il-Keun Kong; Dieter Häussinger; Carsten Münk
Journal:  Viruses       Date:  2018-04-10       Impact factor: 5.048

7.  Clues for two-step virion infectivity factor regulation by core binding factor beta.

Authors:  Youwei Ai; Jianzhang Ma; Xiaojun Wang
Journal:  J Gen Virol       Date:  2017-05-18       Impact factor: 3.891

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.